Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
复制标题
肝细胞癌患者的生存率和基因组突变特征与免疫治疗的关联
DOI：
10.21037/atm.2020.01.32
复制
发表时间：
2020-03-01
影响因子：
--
通讯作者：
Luo, Baoming
中科院分区：
文献类型：
--
作者：
Ou, Qiyun;Yu, Yunfang;Luo, Baoming
背景：目前的指南缺乏对肝细胞癌的免疫治疗和免疫相关生物标记物的使用建议。我们的目的是为肝癌患者的生存与免疫治疗的相关性提供可靠的证据，并证明基因组突变特征可以成为预测肝癌患者免疫治疗疗效的有效生物标志物。方法：我们对17项随机试验的2055名患者进行了荟萃分析，并对31名患者进行了个体患者水平的分析。试验数据在PubMed、EMBASE和Cochrane中央图书馆中得到确认，个别患者的数据从cBioPortal数据库中获得。用风险比(HR)和95%可信区间(95%CI)评估总生存率(OS)和无进展生存率(PFS)。本研究注册编号为CRD42018083991。结果：Meta分析显示，与常规治疗相比，免疫治疗可导致OS延长(HR=0.65，P
Background: Current guidelines lack recommendations for the use of immunotherapy and immunerelated biomarkers for hepatocellular carcinoma (HCC). We aim to provide reliable evidence of the association of survival with HCC immunotherapy and to demonstrate that genomic mutation signature could be an effective biomarker to predict immunotherapy efficacy of HCC patients.Methods: We conducted a meta-analysis of 17 randomized trials with 2055 patients and an individual patient-level analysis of 31 patients. Trial data were identified in PubMed, EMBASE and Cochrane Central library, and individual patient data were obtained from the cBioPortal database. Overall survival (OS) and progression-free survival (PFS) were assessed with the hazard ratio (HR) and 95% CI. This study is registered with PROSPERO, number CRD42018083991.Results: The meta-analysis showed that compared to conventional therapy, immunotherapy resulted in prolonged OS (HR =0.65, P